# Starna Therapeutics

Source: https://onco.cc/companies/starna-therapeutics/  
OnCo record `starna-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Starna Therapeutics develops RNA medicines carried in fat particles designed to reach tissues outside the liver. Its STR-P004 aims to turn a patient's own immune cells into CAR-T cells inside the body, and is in an early study in B-cell non-Hodgkin lymphoma.

## Summary

Starna Therapeutics (Suzhou) Co., Ltd. develops RNA-based medicines on a lipid nanoparticle platform for extrahepatic delivery, with tissue-specific and cell-selective nanoparticles. STR-P004 is an intravenously given in vivo CAR-T drug; the company describes it for autoimmune disease, and the early clinical study NCT07003178 at a single centre in Suzhou tests it in relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma. Its other disclosed programme is STR-V003, a respiratory syncytial virus vaccine. The company reported a Series B of more than 300 million yuan in October 2025, co-led by LYFE Capital, Hillhouse and Lilly Asia Ventures, and a Series B+ of nearly 40 million US dollars in May 2026. Its first registered cancer trial, NCT07003178, was posted on ClinicalTrials.gov in June 2025; its first registry study overall, posted in April 2024, was an RSV vaccine trial.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: 星锐医药
- HQ: Suzhou
- Type: biotech
- Website: https://www.starnatx.com/

## Notes

- Founding year not stated on the company website.
- The funding rows are from headlines and summaries on the company home page; the individual news pages were not read in full.
- Company website read on 29 October 2026.

## Sources

- Official website: https://www.starnatx.com/
- ClinicalTrials.gov: early study of STR-P004 in B-cell non-Hodgkin lymphoma (NCT07003178): https://clinicaltrials.gov/study/NCT07003178

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)

---
JSON: https://onco.cc/api/v1/entities/starna-therapeutics.json